12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Company News  |  Deals

Alnylam, Tekmira Pharmaceuticals Inc. deal

Alnylam and Tekmira agreed to a new deal and will settle all litigation between the partners, including a suit related to Tekmira's lipid nanoparticle (LNP) siRNA delivery technology. Alnylam will pay Tekmira $65 million, including $35 million to terminate the partners' prior deals and to reduce milestone and royalty payments owed to Tekmira for siRNA therapeutic ALN-PCS and RNAi products ALN-VSP and ALN-TTR02.

Under the new deal, Alnylam will transfer IP to Tekmira covering the LNP technology, and Alnylam will retain rights...

Read the full 423 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >